KBN2202, a Salicylic Acid Derivative, Preserves Neuronal Architecture, Enhances Neurogenesis, Attenuates Amyloid and Inflammatory Pathology, and Restores Recognition Memory in 5xFAD Mice at an Advanced Stage of AD Pathophysiology
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262210942 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Sun-Young Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Efficacy Test Center for Mental & Behavioral Disorders (MBD), Ajou University Hospital, Suwon 16499, Republic of Korea. Hauptthemen laut MEDLINE: Neurogenesis, Alzheimer Disease, Neurons, Memory. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF), funded by the Korean government (MSIT), Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea, Korea Bio-health Technology R&D Project.
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, amyloid-β (Aβ) pathology, synaptic degeneration, impaired neurogenesis, and chronic neuroinflammation. KBN2202, a small-molecule salicylic acid derivative [2-[(2-naphthalen-1-yloxy)ethyl]amino]-4-hydroxybenzoic acid], was investigated for its potential as a multi-target therapeutic agent in advanced-stage AD. To this end, 9-month-old 5xFAD mice with established AD-like pathology received daily oral KBN2202 (5 or 20 mg/kg) or vehicle for 12 weeks. KBN2202 demonstrated broad histopathological benefits. It preserved hippocampal CA1 cytoarchitecture and increased dendritic length in cortical neurons. Neurogenic activity was also enhanced, with elevated doublecortin (DCX) expression in the subventricular zone (SVZ). At the molecular level, KBN2202 reduced amyloid precursor protein C-terminal fragments (APP-CTFs), key intermediates in amyloidogenic processing, and histological staining confirmed a significant reduction in fibrillar and diffuse Aβ plaque burden in the cortex and hippocampus. Furthermore, KBN2202 attenuated astrocytic and microglial activation, indicating suppression of chronic neuroinflammation. In behavioral assessments, KBN2202 significantly improved recognition memory in the novel object recognition (NOR) test, while Y-maze performance remained unchanged. Overall, the compound exhibited robust neuroprotective, pro-neurogenic, anti-amyloid, and anti-inflammatory effects. These findings support the therapeutic potential of KBN2202 as a multi-functional candidate for symptomatic-stage AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Efficacy Test Center for Mental & Behavioral Disorders (MBD), Ajou University Hospital, Suwon 16499, Republic of Korea.
- Preclinical Research Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDI hub), Daegu 41061, Republic of Korea.
- Laboratory Animal Research Center, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
- Department of Pharmacology, Ajou University School of Medicine, Suwon 16499, Republic of Korea.
- BK21 R&E Initiative for Advanced Precision Medicine, Suwon 16499, Republic of Korea.
- Department of Biomedical Sciences, Graduate School of Ajou University, Suwon 16499, Republic of Korea.
ORCID-Profile: Joon-Suk Park
Förderung
- National Research Foundation of Korea (NRF), funded by the Korean government (MSIT)
- Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
- Korea Bio-health Technology R&D Project
- Korea Health Technology R&D Project
- Ministry of Health & Welfare, Republic of Korea
- Bio&Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government
Zitieren
APA
Lee, S. Y., Kim, J. C., Choi, M. R., Song, J., Kim, M., Chang, S. H., Kim, J. S., Park, J. S., & Lee, S. R. (2025). KBN2202, a Salicylic Acid Derivative, Preserves Neuronal Architecture, Enhances Neurogenesis, Attenuates Amyloid and Inflammatory Pathology, and Restores Recognition Memory in 5xFAD Mice at an Advanced Stage of AD Pathophysiology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210942
Vancouver
Lee SY, Kim JC, Choi MR, Song J, Kim M, Chang SH, et al. KBN2202, a Salicylic Acid Derivative, Preserves Neuronal Architecture, Enhances Neurogenesis, Attenuates Amyloid and Inflammatory Pathology, and Restores Recognition Memory in 5xFAD Mice at an Advanced Stage of AD Pathophysiology. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210942
BibTeX
@article{Lee2025,
author = {Lee, Sun-Young and Kim, Jong Chul and Choi, Mi Ran and Song, Jiseo and Kim, Moonhang and Chang, Seok-Hwan and Kim, Jong Sung and Park, Joon-Suk and Lee, Sang-Rae},
title = {KBN2202, a Salicylic Acid Derivative, Preserves Neuronal Architecture, Enhances Neurogenesis, Attenuates Amyloid and Inflammatory Pathology, and Restores Recognition Memory in 5xFAD Mice at an Advanced Stage of AD Pathophysiology},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262210942}
}
EUVIMED